BookJames E. Barrett, Clive P. Page, Martin C. Michel, editors.
Summary: Celebrating 100 years of HEP, this volume will discuss key pharmacological discoveries and concepts of the past 100 years. These discoveries have dramatically changed the medical treatment paradigms of many diseases and these concepts have and will continue to shape discovery of new medicinies. Newly evolving technologies will similarly be discussed as they will shape the future of the pharmacology and, accordingly, medical therapy.
Contents:
Intro
Preface
Contents
Part I: A Century of Advances in Pharmacology
Perspectives of Pharmacology over the Past 100 Years
1 Introduction
2 The Emergence of Pharmacology in Germany: Rudolf Buchheim
2.1 Schmiedebergś Contribution to the Development of Pharmacology
3 The Spread of Pharmacology
3.1 Otto Krayer and the Origins of Behavioral Pharmacology
4 Pharmacology Through 100 Years and a Future Perspective
5 Conclusions
References
Emergent Concepts of Receptor Pharmacology
1 Introduction
2 Shots in the Dark: Null Methods in Pharmacology 1.2 Signalling in Health and Malignant Disease
1.3 Tumour Microenvironment and Host Immunity
2 Introduction
2.1 History
2.2 Roles for Systemic Therapies
2.3 Cytotoxic Drugs
Box 1 Summary of Broad Classes of Cytotoxic Drugs
2.4 Targeted Therapies
2.5 Immunotherapy
3 Clinical Trials in Oncology
3.1 Phase 1 Trials
3.2 Phase 2 Trials
3.3 Phase 3 Trials
4 Rationally Designed Therapies
Box 2 Targets for Anticancer Therapies: Examples of Approved and Investigational Drugs
4.1 Ligands as a Target
4.1.1 Oestrogen
4.1.2 Androgen
4.2 Targeting Receptors 3 Recombinant Systems Redefine Receptor Pharmacology
4 Binding Gives Way to Functional Experiments
5 Understanding Agonism: The Black/Leff Operational Model
6 The Shift from Orthosteric to Allosteric Drug Action
7 The Move from Parsimonious Models to Dynamic Models of Receptor Conformation
8 Allosteric Probe Dependence: Biased Receptor Signaling
9 Structure: Receptors Show Themselves
10 Genetics and Computer Science Impact Pharmacology
11 Conclusion
References
The Evolving Landscape of Cancer Therapeutics
1 Biology of Cancer
1.1 Cancer as a Genetic Disease 4.2.1 Vascular Endothelial Growth Factor (VEGF) and Its Receptors
4.2.2 Epidermal Growth Factor Receptor
4.2.3 HER2
4.2.4 CD20
4.3 Other Targets
4.4 Targeting the T-Cell
4.4.1 Checkpoint Inhibition
4.4.2 Adoptive T-Cell Therapy
5 Nuclear Medicine Therapies
5.1 Radio-Iodine in Thyroid Cancer
5.2 Somatostatin Analogues
5.3 Radium-223
5.4 PSMA Ligand: Lutetium
6 Pharmacogenetics, Pharmacogenomics and Patient Selection for Treatment
6.1 Lung Cancer and EGFR Mutations
6.2 BRCA1, BRCA2 Mutation and PARP Inhibition
6.3 Prediction of Toxicity 7 Resistance Mechanisms
7.1 CML BCR-ABL Mutations and Resistance to Imatinib
7.2 Molecular Markers of Resistance to EGFR Inhibition
7.2.1 Multiple Targets
7.2.2 Irreversible Binding
7.3 ALK Resistance
8 Cancer Drug Discovery and Preclinical Development
9 Current Issues in the Development of Drugs in Oncology
9.1 Improving the Odds of Success of Phase 3 Trials
9.2 Regulation of Cancer Drug Development
10 Conclusion and Future Perspectives
References
Monoclonal Antibodies: Past, Present and Future
1 Introduction
2 Background.